Reig Jofre and Ojer Pharma obtain the first European authorization for the commercialization of their innovative antibiotic Impetine Gel
- Impetine® is an innovative mupirocin antibiotic bioadhesive gel used for the treatment of dermatological infections such as impetigo, folliculitis and furunculosis
- First commercialization authorization obtained for the Portuguese market and authorization processes initiated in the rest of the European Union, in addition to Mexico and Canada. Advanced negotiations in progress in the United States, Asia, LATAM and the MENA area
Pharmaceutical companies Reig Jofre and Ojer Pharma have recently received market authorization from the Portuguese Medicines Agency (Infarmed) for Impetine® Gel, an innovative mupirocin antibiotic bioadhesive gel used for the treatment of primary dermatological infections such as impetigo, folliculitis and furunculosis, and secondary infections such as overinfected dermatoses of the skin.
The product, which has been developed by both companies in collaboration with various Spanish R&D centres and universities and patented in the main international markets, has successfully passed the preclinical and clinical development phases and has demonstrated an optimized efficacy and safety profile with respect to the reference product, making it the first topical mupirocin antibiotic on the market, presented in an innovative transparent and bioadhesive gel in the form of a sustained-release matrix.
Impetine® is a clear example of how incremental innovation provides added value to patients, health professionals and the national health system, by offering a better antibiotic treatment with a better dosage and formulation that facilitates greater treatment adherence and thus contributes to the correct use of antibiotics.